What Researchers Did
Researchers investigated the use of monthly bevacizumab infusions (10 mg/kg) in three patients with cerebral radionecrosis that developed after radiation therapy for malignant brain tumours.
What They Found
Of the three patients treated, one received only a single infusion due to lymphopenia, while another received four infusions but showed no clinical improvement or radiologic progression. The third patient experienced severe side effects, including a transient ischemic accident and a perforated corneal ulcer, leading to premature treatment discontinuation. Overall, the study noted severe side effects and an absence of significant clinical or radiologic improvements with bevacizumab.
What This Means for Canadian Patients
Canadian patients with cerebral radionecrosis should be aware that bevacizumab may not be an effective treatment and could lead to serious side effects. Current evidence suggests that this therapy might not offer a beneficial alternative for those whose condition resists conventional treatments.
Canadian Relevance
This study has no direct Canadian connection as it was conducted by researchers in France and published in a French journal.
Study Limitations
A significant limitation of this study is its extremely small sample size of only three patients, which prevents drawing generalizable conclusions about bevacizumab's efficacy or safety.